Clinical Trials Logo

Fallopian Cancer clinical trials

View clinical trials related to Fallopian Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT01580696 Completed - Ovarian Cancer Clinical Trials

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Start date: April 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Folate binding protein (FBP) is highly over-expressed in breast, ovarian and endometrial cancers and is the source of immunogenic peptides (E39) that can stimulate cytotoxic T lymphocytes (CTL) to recognize and destroy FBP-expressing cancer cells in the laboratory. The purpose of this study is to test whether a peptide-based vaccine consisting of the E39 peptide mixed with the FDA-approved immunoadjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) is safe and effective at inducing an in vivo peptide-specific immune response. Furthermore, the investigators intend to determine the best dose of the vaccine to utilize to produce this immunity most efficiently. The investigators will determine whether immunity to FBP will prevent clinical recurrence. Additionally, the investigators will compare these results with results from a trial utilizing the E75 peptide (from the HER2/neu protein) in ovarian and endometrial cancer patients in preparation for studying a combination vaccine.

NCT ID: NCT01104675 Completed - Ovarian Cancer Clinical Trials

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.